NLRP12, an inhibitory modulator of the NF-kB pathway, has been identified as a regulator of the WNT/β-catenin pathway in colorectal cells, suggesting a novel clinical therapeutic target for CRC patients [34]. The gene discussed is NLRP12; the disease is colorectal carcinoma.